| |
Wednesday, May 14, 2025 | 11am ET / 8am PT Biotech success isn’t just about great science—it’s about building a compelling commercial narrative from day one. Join us to explore how early commercialization planning, powered by real-world insights, can maximize an asset’s potential. Our discussion will uncover strategies to integrate commercial thinking into R&D. Register now. 
|
|
Today’s Big NewsApr 22, 2025 |
| By Zoey Becker The Swiss pharma's sweeping $50 billion investment comes as the threat of U.S. tariffs on pharmaceuticals continues to loom over the biopharma industry. |
|
|
|
By James Waldron Roche has pledged to upgrade three R&D sites and pointed to the recent announcement of a new home for its cardiovascular, renal and metabolism R&D work as proof the Swiss pharma is investing serious money in the U.S. |
By Fraiser Kansteiner Under a new 10-year agreement, Regeneron will pay CDMO powerhouse Fujifilm Diosynth Biotechnologies more than $3 billion to help manufacture bulk drug product for its commercial biologics in the United States. The move comes as many drugmakers operating in the U.S. attempt to bolster domestic production ahead of potential pharmaceutical import tariffs. |
By Gabrielle Masson,Darren Incorvaia The National Institutes of Health is rolling out rules that block new grants for any researcher or institution advancing programs related to diversity, equity and inclusion. |
|
Tuesday, May 6, 2025 | 9am ET / 6am PT This webinar will explore how to use AI-driven tools for timely data-driven decisions that are critical to securing approvals, expediting market entry and sustaining competitive strength. Register now. 
|
|
By James Waldron Harvard University is suing President Trump's administration over its threats to freeze billions in research funding. |
By Conor Hale Biolinq's coin-sized device, worn on the forearm, can also track sleep and activity data to help provide additional context around the user’s metabolic health. |
By Nick Paul Taylor Galderma has kicked off an ad campaign to show how its Nemluvio can empower people to rule over itchy eczema. Aiming to grow the biologic into a $2 billion product, the company is running ads across national TV and digital media to spread the word about its effects on a particularly bothersome symptom. |
By Conor Hale BD described the HemoSphere Alta as the first major launch from the patient monitoring business it acquired last year from Edwards for $4.2 billion. |
By Kevin Dunleavy Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment Wegovy, Novo Nordisk has asked the FDA to approve it. |
By Andrea Park More than 90% of dermatology clinicians surveyed by Leo Pharma say their patients with moderate to severe chronic hand eczema experience negative impacts from the condition on their physical and emotional well-being. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we unpack the latest tariffs from the Trump administration and their potential impact on the life sciences industry. |
|
|---|
|
|
|
Wednesday, May 28, 2025 | 11am ET / 8am PT Join us to learn more about Integrated Drug Discovery (IDD), and explore the complexity of integrating multidisciplinary functions, including chemistry, biology, pharmacology, project and data management, advanced technologies, and regulatory compliance. Learn how to navigate the drug discovery journey and overcome common challenges. Register now. 
|
|
eBook Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
Whitepaper Is your clinical trial data truly reliable? Learn how a combined approach using Imaging Core Labs and Endpoint Adjudication Committees (EAC) can minimize risk, control costs, and strengthen your study from the ground up. Don’t leave success to chance—arm yourself with the insights to stay ahead. Sponsored by: WCG |
Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
